Saturday, June 15, 2024
More
    HomeFinanceNewborns with severe pulmonary hypertension benefit from treatment with Vasopressin.

    Newborns with severe pulmonary hypertension benefit from treatment with Vasopressin.

    Related stories

    Malla Reddy faces legal action with case filing

    Telangana's Minister for Labour and Employment, Malla Reddy, and...

    Actress Hema released on bail in rave party case

    Telugu actress Hema, who was in jail for attending...

    Revanth Reddy orders strict action after man is beaten to death

    Chief Minister A Revanth Reddy expressed concern over the...

    A rare and life-threatening condition called Persistent Pulmonary Hypertension (PPHN) affects approximately 1 in 500 newborns. It causes low oxygen levels and high pressure in the pulmonary arteries due to the blood vessels in the lungs failing to dilate after birth. Doctors use a hormone called vasopressin as a rescue therapy when other treatments fail to improve oxygenation and blood pressure in newborns with severe PPHN.

    A study conducted by doctors at Surya Mother and Child Super Speciality Hospital in Pune enrolled 31-term newborns with severe PPHN who were experiencing refractory hypoxia and refractory systemic hypotension despite standard treatments. The physicians used vasopressin as rescue therapy based on clinical judgment and standard practices. Out of the 31 newborns, 29 responded positively to the treatment. The researchers collected data on various variables before and after vasopressin administration and recorded any adverse events associated with its use.

    - Advertisement -
    Also read:  Man scales electricity tower following dispute with spouse

    The study’s results show promise for the use of vasopressin as rescue therapy in term newborns with severe PPHN. However, because it was an observational study, the results may be subject to confounding factors, such as differences in the severity of illness or the underlying cause of PPHN between the newborns in the study. A randomized controlled trial would be needed to establish a causal relationship between vasopressin and improved outcomes in this population.

    Dr. Sachin Shah, Director of Neonatal and Paediatric Intensive Care Services at Surya Hospitals Pune, said the study’s findings may help inform clinical practice and guide future research in the use of vasopressin as rescue therapy in term newborns with severe PPHN. The study’s strength is its prospective design and pragmatic approach to relatively uncommon but life-threatening problems where clinicians are required to do “out of the box” thinking in a resource-limited setting.

    Also read:  Releasing the TG TET-2024 results, Chief Minister A Revanth Reddy announces the outcome on Wednesday.
    - Advertisement -
    Rajesh M
    Rajesh Mhttps://www.telanganatribune.com
    Latest News from Hyderabad, Telangana, India & World!

    Follow us

    3,565FansLike
    179FollowersFollow
    1,202FollowersFollow
    965SubscribersSubscribe

    Contribute News

    You can contribute an article to Telangana Tribune by dropping a mail at newsdesk@telanganatribune.com

    Latest stories

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here